• to lessen the risk of critical cardiovascular (coronary heart and blood vessel) complications in adults with form 2 diabetes and cardiovascular disease In Oct 2024, Novo Nordisk posted a study on scientific journal Nature a couple of novel glucose-sensitive insulin NNC2215 which will l